Portfolio
0
in our dataset
Rounds participated
0
Rounds led
0
Disclosed deployed
—
across known amounts
Stages
—
About
XT is among the early investors in Israeli startups. Focusing on early-growth companies with the potential to become market frontrunners, XT leverages its strong, experienced team to drive success. To date, XT has invested in 100 companies, resulting in exits and category leaders such as Duve, Checkmarx, Lumenis, Enzymotec, Cymbio, Sofwave, and Phytech.
Portfolio
No portfolio companies in this dataset yet.
Investor Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When was XT Venture Capital founded?
- XT Venture Capital was founded in 1997.
- What is XT Venture Capital's primary geographic focus for investments?
- XT Venture Capital is an early investor in Israeli startups, with its headquarters in Tel Aviv-Yafo, Israel.
- How many companies has XT Venture Capital invested in to date?
- XT Venture Capital has invested in 100 companies to date.
- Can you name some notable exits from XT Venture Capital's portfolio?
- Notable exits from XT Venture Capital's portfolio include Checkmarx, acquired by Hellman & Friedman in March 2020 for $1.15B, and Cymbio, acquired by PayPal in January 2026.
- Which sectors does XT Venture Capital concentrate its investments in?
- XT Venture Capital shows a concentration in Health Tech & Life Sciences, Cyber Security, and Business Software, based on its portfolio companies and investment rounds.
- What was XT Venture Capital's most recent investment?
- XT Venture Capital's most recent investment was in Orion Security in February 2026, with an amount of $32,000,000.
- Has XT Venture Capital acted as a lead investor in any recent rounds?
- Yes, XT Venture Capital was a lead investor in enSights' $10,000,000 round in December 2024.
- What is the range of investment amounts for XT Venture Capital?
- XT Venture Capital's investment range is $1M+.
- Which of XT Venture Capital's portfolio companies went public via IPO?
- Sofwave Medical went public on TASE in May 2021 with a valuation of $245M, and Epitomee Medical went public on TASE in December 2021 with a valuation of $203M.